• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

14.49 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amicus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
September 28, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark ↗
September 28, 2023
Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level. 
Via Investor's Business Daily
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
September 01, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
August 29, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics: Q1 Earnings Insights ↗
May 10, 2023
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Amicus Therapeutics ↗
March 28, 2023
 
Via Benzinga
News headline image
Earnings Scheduled For March 1, 2023 ↗
March 01, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
News headline image
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
August 21, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
August 15, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
August 08, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023
July 31, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Preview: Amicus Therapeutics ↗
February 28, 2023
 
Via Benzinga
News headline image
Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade ↗
July 20, 2023
On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81. 
Via Investor's Business Daily
News headline image
Amicus Therapeutics Stock Sees Improving Market Leadership; Earns 81 RS Rating ↗
July 17, 2023
On Monday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, to 81, up from 74 a day earlier. 
Via Investor's Business Daily
News headline image
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
June 27, 2023
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in the European Union for Adults with Late-onset Pompe Disease (LOPD) 
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark ↗
May 19, 2023
One key metric to look for in a stock is an 80-plus RS Rating. Amicus Therapeutics stock hit that mark, with a jump from 74 to 82 Friday. 
Via Investor's Business Daily
News headline image
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics ↗
May 10, 2023
The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult  
Via Benzinga
News headline image
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
May 10, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference
May 02, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023
May 01, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
April 26, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
March 27, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
March 01, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
February 27, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
February 22, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023
February 14, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023
February 13, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
February 08, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
'I Think You Should Take The Money And Run': Cramer On This Stock Up 52% Over Past Month ↗
January 25, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Amicus Therapeutics Inc (NASDAQ: FOLD) is an "ideal spec. 
Via Benzinga
News headline image
Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
January 09, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap